心臓の衰弱は心臓のカシェキアではない:心臓の問題における主観的/客観的遺伝子の問題
Anna Luisa Mazzotti1, Medhi Hassani2, Zhenlin Li3
1Assointerpreti, Italian Association of Conference Interpreters, Rome, Italy, and MPS Public Speaking Rome.
European journal of translational myology
|September 2, 2025
まとめ
癌性カシェキシアは,心臓性カシェキシアとは異なる心臓の質量損失を伴う. この研究は,心筋縮と癌による心筋衰弱の混同を防ぐために用語を明確にします.
科学分野:
- 腫瘍学
- 心臓病科
- 生理学
背景:
- 初期の研究では 腫瘍を患ったカシェクティックなマウスの心臓の 質量減少が観察されました
- 癌のカシェキシアは,癌患者の筋肉の消耗と体重減少の症候群です.
- 最近の研究では,マウスモデルでの腫瘍誘発の心臓質量減少が確認されています.
研究 の 目的:
- 癌における心臓衰弱とカシェキアに関する用語を解明する.
- 癌による心臓衰弱と心臓カシェキア (心臓病による縮) を区別する.
- "心臓カシェキア"や "筋肉カシェキア"といった 誤った解釈を防ぐために
主な方法:
- 癌カシェキアと心臓への影響に関する既存の研究の文献レビューと分析.
- "心筋縮""心筋縮""筋肉縮"の定義と意味の比較
- 腫瘍に起因する心臓質量減少と 心臓病理学に起因する縮の 違いを強調します
主要な成果:
- 癌性カシェキシアは,筋肉の消耗と体重の減少によって特徴付けられます.
- 腫瘍の負荷は心臓の質量損失を引き起こし,心臓カシェキアとは異なる現象です.
- 一般的に使われる用語はしばしば誤用され,心臓が癌に関与していることに混乱を招く.
結論:
- "心臓カシェキシア"は 曖昧な用語で 慎重に扱わなければなりません
- がんによる心臓衰弱と 心臓病理学による縮を区別することが重要です.
- がんとその治療法による心臓の影響を正確に説明するには,明確な用語が必要です.
関連する概念動画
Cardiomyopathy I: Introduction and Classification
50
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
50
Cardiomyopathy VI: Nursing Management
32
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
32
Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Cardiomyopathy IV: Restrictive Cardiomyopathy
27
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
27
Imbalances in Cardiac Output
1.5K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.5K
Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21


